AI assistant
Climb Bio, Inc. — Director's Dealing 2024
Jun 28, 2024
33982_dirs_2024-06-27_44d19342-ad84-4d5d-b4f7-637c9c3a3855.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Eliem Therapeutics, Inc. (ELYM)
CIK: 0001768446
Period of Report: 2024-06-27
Reporting Person: Brennan Aoife (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-06-27 | Stock Option (Right to Buy) | $7.53 | A | 550000 | Acquired | 2034-06-26 | Common Stock (550000) | Direct |
| 2024-06-27 | Restricted Stock Units | $ | A | 275000 | Acquired | Common Stock (275000) | Direct |
Footnotes
F1: This option was granted on June 27, 2024 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through June 27, 2028, subject to the Reporting Person's continued service.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting.
F3: The RSUs were granted on the Grant Date and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service.